R&D refund will help support MSC trial
Stem cell company Cynata Therapeutics (ASX:CYP) has received an R&D Tax Incentive refund of $932,580.65 for the 2014–15 financial year. The tax incentive is an Australian Government program under which companies receive cash refunds of 45% of eligible expenditure on research and development.
Cynata CEO Dr Ross Macdonald said the refund “extends our operating runway at a time when we plan to soon commence the clinical trial of our first proprietary Cymerus mesenchymal stem cell (MSC) product, CYP-001”. CYP-001 was last month confirmed by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to be suitable for the company’s Phase 1 clinical trial in patients with graft versus host disease.
Cynata Therapeutics (ASX:CYP) shares were trading 7.35% higher at $0.365 as of around 2.30 pm on Wednesday.
$96m RNA Research and Manufacturing Facility opens in NSW
The new 4500 sqm RNA Research and Manufacturing Facility within the Macquarie University...
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
